Clinical conversation for preparing and framing questions.

Before pregnancy

Planning a Pregnancy with HS

The most useful moment for this conversation is before conception. This article shows what can be prepared calmly — and what only your care team can decide.

← Back to the Pregnancy & Family Planning hub

Planning a pregnancy with HS does not mean everything can be settled in advance. It means knowing which questions to ask early, so that fewer decisions have to be made under time pressure later.

This article contains no recommendations about individual medicines or treatments. Those decisions rest solely with the clinician who prescribes your treatment — in conversation with you.

In short

  • An appointment before conception is more useful than one after a positive test.
  • Changes to your treatment are decided solely by the team that prescribes it — never by you alone and never by a website.
  • Smoking is the best-documented modifiable factor affecting both HS and pregnancy.
  • Thinking about co-occurring conditions is part of the preparation, not a side issue.

The pre-conception appointment

Limited evidence Rests mainly on case series, preliminary studies, or expert consensus.

Review articles on HS in pregnancy consistently recommend a conversation before conception. The reason is practical: some questions — about the treatment plan, or about planned procedures — can be answered differently with lead time than they can on the spot.

Say what the appointment is about when you book it. An appointment flagged as a pre-conception conversation usually gets more time than a routine review.

  • Bring a list of every treatment you currently use — including anything you buy without a prescription.
  • Note how your disease course has been over recent months and where symptoms are active now.
  • Record whether any procedures are planned or have been discussed, and when.
  • Clarify who your contact is if symptoms appear during a pregnancy.
  • Ask whether dermatology and obstetric care should be in direct contact — and who initiates that.

Putting the treatment plan on the table

Limited evidence Rests mainly on case series, preliminary studies, or expert consensus.

Reviewing the treatment plan before a planned pregnancy is standard in the specialist literature. What comes out of that review is individual: it may mean everything stays as it is, or that something changes. This website deliberately names no individual medicines and makes no statements about them.

One point, though, is general and important enough to state plainly: do not change, pause or end a prescribed treatment on your own — not after a positive test, and not on the basis of information found online. Doing so has consequences of its own, and the judgement belongs to the people who prescribed your treatment.

Smoking

Strong evidence Well supported by international guidelines and high-quality studies.

Smoking is the factor with the strongest evidence base in this article — and the one on which dermatology and obstetrics agree without reservation. In HS, smoking is associated with a more severe course, and the risks of smoking in pregnancy are well established independently of that.

Stopping is also hard, and blame does not help anyone do it. The more useful question is what concrete support is available: structured programmes, counselling and medical support work better than resolve alone. How a quit attempt is supported during pregnancy is something to discuss with your care team.

Taking co-occurring conditions into account

Moderate evidence Backed by consistent observational studies or smaller trials.

HS occurs more often alongside other conditions — among them metabolic and cardiovascular conditions, polycystic ovary syndrome, and depression and anxiety. That matters for pregnancy planning, because some of these need preparation and follow-up of their own.

Population-level studies report certain pregnancy and maternal complications more often in women with HS than in women without it. These associations overlap heavily with co-occurring conditions and cannot be cleanly separated from them in the available data. For you personally such figures predict nothing — they are an argument for well-coordinated care, not a reason for alarm.

Weight, daily life and self-management

Limited evidence Rests mainly on case series, preliminary studies, or expert consensus.

Weight comes up frequently in connection with HS — often in ways people experience as shaming. Factually: higher body weight is associated with a more severe HS course, and weight plays a role in pregnancy care in any case. Whether and how it should be a topic in your case is for your care team to decide with you — not for a website or a guide.

Practical everyday matters, by contrast, can be prepared regardless: friction in skin folds, wound care and clothing all change during pregnancy because the body changes. Those topics have dedicated guides on this site.

Planned procedures and timing

Limited evidence Rests mainly on case series, preliminary studies, or expert consensus.

If surgery has been discussed or is scheduled, timing belongs in the same conversation. Wound healing takes time, and appointments, aftercare and capacity are easier to plan with notice.

Whether a procedure makes sense before a planned pregnancy is purely an individual medical decision. What you can do is raise the question early.

Who talks to whom?

Limited evidence Rests mainly on case series, preliminary studies, or expert consensus.

In practice, much fails not for want of knowledge but for want of coordination. Dermatology, obstetrics, general practice and midwifery each see one part of the picture. Studies of disease course during pregnancy note explicitly that many people receive no dermatology care at all while pregnant.

You do not have to organise that coordination yourself — but you can start it by asking, in every consultation, who is being told.

Questions to discuss with your healthcare team

These are prompts, not advice. Take the ones that fit your situation to your next appointment — the printable checklist collects them all.

  • Should my treatment plan be reviewed before a planned pregnancy?
  • How much lead time is sensible for that?
  • What applies to the treatments I use without a prescription?
  • Which co-occurring conditions should be assessed before a pregnancy?
  • What support is available to me for stopping smoking?
  • Should a planned procedure happen before or after a pregnancy?
  • Who coordinates dermatology, obstetric care and general practice?
  • Who do I contact if I have a flare during pregnancy?

Questions to Ask Before Pregnancy →

Frequently asked questions

Do I have to stop my treatment if I want to become pregnant?

This website cannot and must not answer that. There is no blanket answer — the judgement depends on the treatment, your disease course and your situation, and it belongs to the people who prescribed it. Only one thing is general: do not make that decision on your own.

When should I have this conversation?

Before conception, as soon as wanting children becomes concrete. Review articles recommend this consistently, because lead time allows more to be settled calmly.

What if my clinic has little experience with HS and pregnancy?

That is common and not a reason to drop the subject. Ask about a referral to a specialist centre, and whether dermatology and obstetric care can be in direct contact. This site has a specialist directory to help with that.

Continue in this hub

Scientific research and editorial review

Last editorially reviewed: · Next scheduled review:

Reproductive health in HS is an area where patient need clearly outruns the evidence. The disease course during pregnancy has been described in cohort studies and pooled in a meta-analysis; fertility and breastfeeding have barely been studied at all. Every page in this hub therefore carries an evidence grade, and sections state explicitly where the evidence stops.

Population-level findings about pregnancy outcomes are reported here as associations that overlap with co-occurring conditions — they are presented as a reason for coordinated care, never as a prediction about any individual pregnancy.

No page in this hub names an individual medicine or states whether a treatment is suitable during pregnancy or breastfeeding. Those questions are routed back to the clinicians who prescribe your care, because they are the only people who can weigh them for your situation.

This hub is source-linked and reviewed at least once a year. If a cited guideline, review or study changes, these pages are updated.

How we work: Editorial Policy

Sources

  1. Adelekun AA, Villa NM, Hsiao JL, Micheletti RG. Pregnancy in Hidradenitis Suppurativa — Patient Perspectives and Practice Gaps JAMA Dermatology, 2021;157(2):227–230 — survey of counselling gaps on conception, heritability, medicines and sexual health
  2. Seivright JR et al. Impact of Pregnancy on Hidradenitis Suppurativa Disease Course: A Systematic Review and Meta-Analysis Dermatology, 2022;238(2):260–266 — pooled rates of improvement, worsening and postpartum flares
  3. Lyons AB et al. Evaluation of Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum JAMA Dermatology, 2020;156(6):681–685 — cohort study; frequent postpartum worsening alongside little dermatology care
  4. Fitzpatrick L, Hsiao J, Tannenbaum R, Strunk A, Garg A. Adverse pregnancy and maternal outcomes in women with hidradenitis suppurativa Journal of the American Academy of Dermatology, 2022;86(1):46–54 — population-level analysis; associations overlap with co-occurring conditions
  5. Barnes LA, Rinderknecht FB, Hsiao JL, Naik HB. Global barriers to sexual health, pregnancy, and breastfeeding in hidradenitis suppurativa International Journal of Women's Dermatology, 2026 — international survey of barriers to sexual health, pregnancy and breastfeeding care
  6. Özbek Ç et al. Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges International Journal of Dermatology, 2025 — review of care during pregnancy and lactation
  7. Collier EK et al. Pregnancy and breastfeeding in hidradenitis suppurativa: A review of medication safety Dermatologic Therapy, 2021;34(2):e14674 — a review written for clinicians; a basis for medical judgement, not for self-directed decisions
  8. MedlinePlus Genetics (U.S. National Library of Medicine): Hidradenitis suppurativa Patient information on genetics; roughly 30 to 40 per cent of affected people have at least one other affected family member
  9. European S2k guideline for hidradenitis suppurativa / acne inversa, part 2: treatment Journal of the European Academy of Dermatology and Venereology, 2025 — framing of treatment and self-management